Apyx Medical Corp (APYX) — SEC Financial Statements & Analysis

Apyx Medical Corp (APYX) is a surgical & medical instruments & apparatus company, incorporated in DE. Apyx Medical Corp trades on Nasdaq as: APYX. Apyx Medical Corp (APYX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Apyx Medical Corp carries a market cap of $189.10M, a P/E ratio of -22.15x, a P/B ratio of 17.73x, a P/S ratio of 3.24x, an enterprise value of $196.83M, and an EV/EBITDA multiple of -71.45x. On profitability, it posts a gross margin of 63.50%, an operating margin of -6.06%, a net margin of -14.62%, a Return on Equity (ROE) of -94.24%, a Return on Assets (ROA) of -14.32%, and a Return on Invested Capital (ROIC) of -21.42%. Per share, it reports EPS of $-0.20, diluted EPS of $-0.54, free cash flow per share of $-0.26, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 25.59% year-over-year, net income growth of -50.56% year-over-year, and EPS growth of -55.64% year-over-year. On the balance sheet, it maintains a current ratio of 5.68x, a quick ratio of 4.41x, working capital of $43.80M, a debt-to-equity ratio of 4.69x, a debt ratio of 0.82, an interest coverage ratio of -0.63x, free cash flow of $-11.05M (TTM), and net debt of $7.73M. Figures sourced from SEC EDGAR.

Market Cap

$189.10M

P/E TTM

-22.15x

EPS TTM

$-0.20

P/B TTM

17.73x

ROE TTM

-94.24%

ROA TTM

-14.32%

Debt To Equity

4.69x

Free Cash Flow TTM

$-11.05M

Net Revenue TTM Growth 1Y

25.59%

Data as of 2026-06-30 · Source: SEC EDGAR